Capstone Investment Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Capstone Investment Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,123	Closed	-$50K	–	2177
2021 Q3	$50K	Buy	+10,123	New	+$49.2K	﹤0.01%	1850
2021 Q1	–	Sell	-15,248	Closed	-$66K	–	2010
2020 Q4	$66K	Buy	+15,248	New	+$65.2K	﹤0.01%	1603

Capstone Investment Advisors's ADMS Position: Q4 2021 in Review

Capstone Investment Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 10,123 shares — an estimated $50K sold.

Capstone Investment Advisors first reported a position in ADMS in Q4 2020 and held it in 2 quarters. The position peaked at $66K in Q4 2020. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Capstone Investment Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Capstone Investment Advisors sold 10,123 Adamas Pharmaceuticals shares in Q4 2021, an estimated $50K.
Capstone Investment Advisors first reported a position in Adamas Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Capstone Investment Advisors's Adamas Pharmaceuticals position peaked at $66K in Q4 2020.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.